Abstract Endocrine breast cancer treatment relies on estrogen receptor alpha (ERa) assessment, which does not predict response in all cases. We investigated whether ESR1 promoter C driven (ESR1_C) gene expression may shed light on endocrine responsiveness. We investigated archived tumor tissues of 211 patients. Transcript levels of ESR1_C and ESR1_exon3 (all transcripts) were quantified by real-time PCR. mRNA stability was assessed in actinomycin D treated MCF-7 cells. ERa protein was quantified using transiently transfected breast cancer cells. Low ESR1_C transcript levels were associated with better overall survival (P = 0.017). High levels of ESR1_C transcript were associated with non-favorable response in tamoxifen treated patients (HR = 2.48; CI 95% 1.24-4.99), an effect that was more pronounced in patients with ERa/PgR double-positive tumors (HR = 3.41; CI 95% 1. 45-8.04). The ESR1_C isoform had a prolonged mRNA half-life and a more relaxed 5 0 -UTR structure compared to ESR1_A isoform. ESR1_C levels may aid in the discrimination of patients' endocrine responsiveness.
Introduction
The information of estrogen receptor alpha (ERa) protein expression status guides the decision for endocrine treatment in breast cancer [1] . However, early reports showed that not all of the ERa moderate to high expressing tumors respond to hormonal manipulation [2] . In current clinical practice 30-50% of tamoxifen treated patients do not respond [3, 4] . This lack of response has been attributed to different mechanisms, e.g., down-regulation of ERa expression either by loss of the receptor or its function [5] , estrogen receptor cross-talk with HER2/neu pathway [6] , variation on plasma levels of anti-estrogenic metabolites known as metabolic resistance [7, 8] , alteration of co-regulatory proteins like NCoRI co-repressor [9] , or altered regulation of autocrine and paracrine growth factors like TGF-b [10] .
There is an ongoing debate, whether methodological limitations including lack of standardized ERa immunohistochemistry (IHC) scoring and inter-laboratory variations may contribute to incorrect ERa assessment eventually leading to treatment failure [11, 12] . Apart from the methodological issue precise data on the biological meaning of ER expression levels and its relation to endocrine treatment response is missing. It is therefore important, to clarify whether ERa mRNA expression measurements differ from protein assessment and whether their quantitative estimates may aid in the identification of patients likely to benefit from tamoxifen.
ERa is encoded by the estrogen receptor one (ESR1) gene that contains seven known promoters. Transcripts differ at the 5 0 -untranslated region (5 0 -UTR) as a result of alternative splicing to a common acceptor splice site giving rise to several mRNA transcripts and, in most cases, to an identical translated protein [13] . Although there is agreement on the multiple promoter usage by the ESR1 gene, there is uncertainty on the contribution of each promoter to ERa transcription and translation. In the normal mammary gland promoter A usage is dominant, whereas ERa over-expression in tumors has been attributed to promoter C formerly designated promoter B [14] .
We studied the contribution of ESR1 differential mRNA expression levels to understand the diverse biological and clinical behavior of ERa IHC positive breast tumors. We compared outcomes of tamoxifen treated patients based on mRNA isoform levels driven by promoter C and those originating from combined ESR1 promoters. Here we provide first evidence for ESR1 isoform C as a putative marker for the improvement of ERa prognosis and prediction of tamoxifen treatment outcome.
Material and methods

Patients' collection
We analyzed formalin-fixed paraffin-embedded tissue specimens from 211 breast cancer patients diagnosed between 1988 and 2004 at the Robert Bosch Hospital, Stuttgart, Germany. Patients and tumor characteristics are given in Table 1 . Inclusion criteria for this retrospective analysis were documented clinical follow-up and availability of tissue blocks with confirmed histology. The following patient groups were included: ERa-positive breast cancer patients treated with tamoxifen (n = 148) and controls without tamoxifen treatment including ERa negative and positive patients (n = 51). Last inquire date was July 2006 with a median follow-up of 76.8 months. The documented tamoxifen treatment was according to standard guidelines [15] .
Immunohistochemistry
A tissue section was stained using anti-ERa protein antibody (1D5; Dako, Carpinteria, CA) according to manufacturer's instructions. Bimodal IHC ERa-status was assessed by Remmele scoring categories, in which 0-2 refer to ERa-negative and 3-12 to ERa-positive status [16] .
DNA and RNA extraction
Tissue homogenization from 1.5 mm diameter tumor tissue punches was done by alkaline heat pretreatment in a buffer containing 10 mM Tris (pH 9), 0.5% Tween, 1 mM EDTA, 5% Chelex and 1% betamercaptoethanol. Overnight digestion with proteinase K (0.5 mg/ml) was at 56°C. Following centrifugation and rapid cooling on ice the Real-time PCR cDNA from 1 lg total RNA was synthesized using random hexamer primed M-MLV reverse transcriptase according to supplier recommendations (Promega, Mannheim, Germany). Real-time PCR with relative quantification (DDCt method) was performed by TaqMan Ò (Applied Biosystems, Foster City, CA) assays to measure transcript levels of ESR1 isoforms. The ESR1_exon3 probe was used for the detection of all ESR1 transcripts (ESR1_exon3). The ESR1_C probe was designed to specifically bind to the 5 0 -UTR of promoter C identifying promoter C driven transcripts (ESR1_C). Due to the absence of an intronic region downstream of promoter A we restricted the analysis of patient samples to ESR1_C and ESR1_exon3 transcripts in order to avoid genomic DNA contamination. The house keeping gene b-glucuronidase (GUS) was used to normalize expression levels by SybrGreen chemistry (ABgene, Hamburg, Germany). For mRNA stability assay ESR1_A levels were assessed after thorough DNase treatment using 5 0 -UTR_A specific primers and 18S ribosomal RNA quantification (18S-rRNA) as endogenous control. Primers were as follows: ESR1_C (Fw: 5 0 -ctc ggccct tgacttctaca-3 0 , Rv:
. For calibration of tumor expression we used tissues from benign breast lesions of seven patients. Cutoff values for under-(low) and over-expression (high) in breast cancer tissues were defined based on standard deviations (STD's) from the mean Ct value of the calibrator samples: strong up/ down ([/\10 STD's), moderate up/down (±2-10 STD's), no regulation (±0-2 STD's). For a bimodal classification, low expression was defined as being within the range of calibrators or absent, and high expression was defined as exceeding 2 STD's of the calibrators mean value.
Cell culture and transfections MCF-7 ERa-positive and MDA-MB-231 ERa-negative breast cancer cells were seeded in triplicates at a density of 5 9 10 4 cells in 24-well plates. Cultures were grown in Dulbecco's Modified Eagle's Medium with the addition of 10% FCS and enriched with 10 -9 M estradiol (GibcoInvitrogen, Karlsruhe, Germany) at 37°C in 5% CO 2. The full-length of ESR1_A and ESR1_C cDNA were amplified using Pfu polymerase (Stratagene, CB Amsterdam, Netherlands) with EcoRI and XhoI tagged oligonucleotides (sequences available upon request) and cloned into appropriately digested pcDNA3.1 expression vector (Invitrogen, Karlsruhe, Germany). MCF-7 and MDA-MB-231 were transfected with increasing amounts of pcDNA3.1_ESR1_A and pcDNA3.1_ESR1_C constructs (0, 10, 100 and 200 ng) using effectene transfection reagent (Qiagen, Hilden, Germany).
mRNA stability assay MCF-7 cells were cultured in triplicate 3.5 cm diameter plates at a density of 7.5 9 10 5 cells/plate. For transcriptional inhibition actinomycin D, 1 lg/ml (Biochemica, Schwerin, Germany), was added and cells were harvested at time points 0, 1, 3, 6, 9, 12, 25 h by addition of cell lysing solution (TEC-kit, Nidderau, Germany). The ERnegative MDA-MB-231 cell line was transfected with 170 ng of both ESR1 expression plasmids and cells were treated with actinomycin D and lysed at four time points: 0, 3, 9, and 24 h after transcription inhibition. Cells at time zero were harvested immediately after actinomycin D addition for reference. Following total RNA extraction 300 ng-1 lg of purified DNase treated RNA was taken for cDNA synthesis. Real-time PCR was performed in triplicate for each of the cultured triplicates for a total of nine replicates per recovered time point. Transcript levels for ESR1_A, ESR1_C and ESR1_exon3 were quantitated by normalization with 18S-rRNA measurements. Calibration of mean expression levels at the six time points was done by comparison to the mean at time zero.
Western blotting
For whole cell lysates preparation, cells were lysed by heating at 95°C in a SDS containing buffer. Samples were electrophoresed in a 10% SDS-polyacrylamide gel and electroblotted onto nitro-cellulose membranes (Schleicher and Schuell, Dassel, Germany). After blocking with 5% skim milk powder (Fluka, Steinheim, Germany) membranes were incubated for 1 h with F-10 mouse anti-ERa antibody (1:500; Santa Cruz Biotechnology, Heidelberg, Germany) and mouse anti-b-Actin antibody (1:5000; Sigma, Munich, Germany) followed by secondary goat anti-mouse HRP antibody at 1:5000 dilution (Dianova, Hamburg, Germany). Detection was performed using SuperSignal WEST DURA/PICO chemiluminescent substrate (Pierce, Bonn, Germany) and visualized with a chemoluminiscent reader (Las1000, Fuji).
In silico analysis of RNA secondary structure Secondary structure of the two specific transcripts ESR1_C and ESR1_A 5 0 -UTRs was generated using mfold software (www.frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/ rna-form1.cgi). RNA secondary structure prediction involved the determination of the most stable structure given by its free energy. This energy was calculated by the sum of the energy of the structural loops, assuming their independency from the rest of the structure [17] .
Statistical analysis
Qualitative and quantitative statistical comparisons between transcript levels and ERa-status were done by Pearson's Chi square and Spearman correlation. To test for an association with clinical outcome, event-free survival (EFS) and overall survival (OS) were analyzed by calculating Kaplan-Meier distributions followed by a Logrank test. EFS was defined as the time from surgery to the occurrence of either local or distant recurrence, contralateral breast cancer, or death from any cause. OS was defined as the time from surgery to death from any cause. Patients who were alive without a breast cancer related event or with a second non-breast primary cancer were censored at the date of last follow-up inquiry. Multivariate Cox regression was used to adjust for prognostic clinical factors and a likelihood test was performed to test for an independent contribution of molecular factors to the outcome variable. All P values were two-sided and values \0.05 were considered statistically significant. All tests were run using SPSS v12.1. To calculate mRNA half-lives and exponential decay curves we used Prism v4.0. Twoway ANOVA test was applied to compare replicate values.
Results
Correlation of ESR1 transcripts with ERa-status
ESR1_exon3 transcript levels were strongly correlated with IHC based ERa scores (r = 0.726, P = 10 -6 ). The ESR1_C transcript was only expressed in ERa-positive cases, showing over-expression in 50 of the 139 ERapositive tumors (36%) for which Real-time PCR could be performed. Within this group there was no significant correlation between expression level of the ESR1_C transcript and protein scores. There was no association of ESR1_C transcript expression with tumor size, nodal status, tumor stage and histological grade.
Correlation of ESR1 transcripts with patient survival For survival analyses of all patients we defined patient groups with low and high ESR1_exon3 and ESR1_C transcript levels. In univariate analysis neither standard bimodal IHC derived ER-status nor ESR1_exon3 mRNA expression were associated with OS (Fig. 1a, b, respectively) . In contrast, low levels of ESR1_C transcript were significantly associated with a more favorable OS when compared to high levels ( Fig. 1c, P = 0.017) . These results are derived from all patients irrespective of hormone receptor status.
Correlation of ESR1_C with response to tamoxifen
We investigated the relevance of ESR1_C transcript levels for the prediction of treatment response of adjuvant tamoxifen treated patients. Cases with less than 3 months follow-up and ERa-negative tumors were excluded. Low levels of the ESR1_C transcript were associated with lower recurrence and death rates when compared to patients with high expression levels ( Fig. 2a , P = 0.0013). Multivariate Cox regression including tumor size, nodal status and histological grade showed that high ESR1_C expression is an independent predictive factor for decreased OS (HR = 2.48; 95% CI, 1.24-4.99; P = 0.011). To address the discriminatory value of ESR1_C transcript expression for patients with potentially most favorable endocrine treatment response, i.e., ERa-positive and progesterone receptor (PgR)-positive tumors, we performed subgroup analyses. Low levels of the ESR1_C transcript was associated with lower recurrence and death rates within the ERa/PgR double-positive phenotype (Fig. 2b , P = 0.0003). Multivariate Cox regression including tumor size, nodal status and histological grade showed that high ESR1_C expression is an independent predictive factor for decreased OS among the double-positive phenotype population (HR = 3.41; 95% CI, 1.45-8.04; P = 0.005).
Comparison of ESR1_C and ESR1_A transcript availability for translation To investigate a possible molecular mechanism underlying the distinct prognostic value of the studied transcripts we evaluated mRNA stability as a potential influencing factor on the regulation of ERa protein expression. The mean normalized decay of mRNA at seven time points after actinomycin D mediated transcription inhibition is shown in Fig. 3 . ESR1_C showed a longer mRNA half-life (t 1/2 ) compared with the total mRNA pool obtained from all promoters (ESR1_exon3) which was even more pronounced when compared with promoter A driven mRNA (t 1/2 -ESR1_C = 7.42 vs. t 1/2 -ESR1_A = 2.85 h). This difference leads to increased stability of promoter C transcript by 2.6-fold compared to promoter A transcripts (ANOVA P \ 0.001). Interestingly, ESR1_exon3 (t 1/2 = 5.12 h) approximately averages the decay rates of C and A transcripts.
Comparison of ESR1_C and ESR1_A transcript secondary structure An analysis of mRNA primary structure showed that 5 0 -UTR_C with 116 nucleotides is shorter while having a lower GC content (51.7%) compared to 5 0 -UTR_A with 163 nucleotides and a higher GC content (71.8%). The predicted RNA secondary structures for the corresponding 5 0 -UTRs have an estimated free energy of -72.9 kcal/mol for ESR1_A and -16.2 kcal/mol for ESR1_C (Fig. 4) . Hence, the ESR1_C transcript has a more relaxed structure with AT-rich sequences facilitating translation initiation from the 5 0 -UTR of transcript ESR1_C. ERa protein translation from ESR1_C and ESR1_A transcripts
Transfection of the ERa-positive (MCF-7) and ERa-negative (MDA-MB-231) cell lines with increasing amounts of the respective ESR1_C and ESR1_A constructs revealed a proportional amount of blotted protein at the same molecular weight of the 66 kDa ERa wild-type protein (Fig. 5a) . To study the effect of transcriptional inhibition on translated protein we performed actinomycin D treatment prior to cell lyses. As shown in Fig. 5b , protein amounts were comparable among triplicates and the protein decay associated with transcriptional blocking was similar for both ESR1_C and ESR1_A transcripts.
Discussion
We investigated whether ESR1 gene expression data improve breast cancer prognosis and prediction of tamoxifen treatment outcome. Using the current clinical standard IHC based ERa protein expression as a reference, we measured ESR1 mRNA and provide first evidence for the promoter C driven isoform being a potential diagnostic classifier for the discrimination of tamoxifen responders and non-responders. It is currently recognized that the IHC derived ERastatus does not accurately predict patients' responsiveness to tamoxifen treatment and that its prognostic value is limited [3] . Interestingly, ERa is not among the listed ''Risk Categories'' defined by the international expert consensus on the primary therapy of early breast cancer [15] . In agreement with this our data confirm ERa protein as a weak classifier for disease outcome once more underscoring the biological and clinical heterogeneity of ERa-positive tumors [3, 18] . Importantly, Bentzon et al. in a comprehensive study of 26,944 patients recently provided strong evidence for the ERa prognostic effect being limited to the first 5 years after diagnosis [19] . Of note, current array based breast cancer gene signatures for the improvement of prognosis and prediction include ESR1 mRNA expression, however, no information has been given on specific isoforms [20, 21] . On the ESR1 transcriptional level, our measurement of total mRNA expression (ESR1_exon3) mirrors the weak prognostic value of protein expression. However, when we stratified patients' outcome with expression levels of the isoform C, tumors with low expression of promoter C driven transcript had a more favorable OS. This association showed to be of particular relevance to the sub-group of ERa-positive patients treated with tamoxifen. At 5 years, patients with high expressing ESR1_C tumors experienced significantly shorter survival probabilities. This effect was strongest in ERa/PgR double-positive tumors with high levels of ESR1_C isoform suggesting a loss of endocrine responsiveness. Of note, the time frame in which the ESR1_C isoform expression showed it's maximal discriminatory power (Fig. 2) overlaps with the time span of 6-15 years post-diagnosis in which the majority of relapses usually occur [22] . From these findings we infer that ESR1_C transcript expression may aid in the identification of ERa-positive tumors not responsive to tamoxifen, thus extending other tamoxifen resistance principles such as growth factor/ER crosstalk [6] and metabolic resistance [23] . It will be interesting to know whether ESR1_C transcript levels may help to identify endocrine sensitivity for both tamoxifen and aromatase inhibitor treated patients.
Because ESR1 isoform C is translated into the common 66 kDa wild-type ERa protein we set out to find possible mechanisms to explain its clinical association. We studied ESR1_C and ESR1_A transcripts quantitatively and qualitatively by determining transcripts half-lives and putative structural implications, respectively. The half-life of the ESR1_C isoform in MCF-7 cells was increased by 2.6-fold when compared with that of ESR1_A, potentially leading to a greater availability as a template for translation. While the half-life of the total ESR1 mRNA pool (ESR1_exon3) in agreement with previous reports was 5.1 h [24] , it averages the half-lives of isoforms A and C suggesting that they are major contributors of ESR1 transcription in breast tumors. With respect to mRNA stability, 3 0 -UTRs are known to be responsible for mRNA degradation through deadenylation of the polyA-tail or endoribonucleolytic cleavage in a tail-independent process [25] . Yet, ESR1_A and ESR1_C transcripts share identical 3 0 ends and therefore the difference in RNA stability must rather be explained by differences at 5 0 -UTRs. Ross pointed to the role of 5 0 -UTRs which can dramatically affect mRNA halflife through influence on translation efficiency or presence of translation-inhibiting stem-loop structural characteristics [26] . Based on its 5 0 -UTRs the ESR1 gene may be considered a class I gene (poorly translated under normal conditions) that can enhance translation by alternative splicing allowing a cell to abandon inhibitory secondary structure [27] . This mechanism may apply to the ESR1_C transcript given its relaxed low energy structure in contrast to the tightly base-paired structure of the ESR1_A. It has been suggested that the differentially spliced 5 0 -UTR exons might regulate ERa synthesis either by influencing turnover or competence of translation of ERa mRNA isoforms [28] . This alternative splicing mechanism could be a critical event for deregulating the tight control of ERa expression in breast epithelial cells. Our clinical investigations showed that patients with breast tumors expressing high levels of ESR1_C transcript had a bad prognosis and moreover, had a poor outcome under tamoxifen treatment. In line with our in vitro experiments we suggest that a selective growth advantage may be acquired once promoter C is activated, which has been particularly evident from ERa/PgR double-positive tumors not responsive to tamoxifen. The hypothesis of promoter C selective usage by breast cancer cells or a sub-population is supported by in vitro findings of a trans-acting factor (ERBF-1) exclusively expressed in cells with promoter C driven ESR1 mRNA expression (formerly promoter B). ERBF-1 binds to a transcriptional enhancer element selectively used in breast cancer as a tumor-specific promoter C enhancer [29] . In summary, ESR1_C and ESR1_A transcripts give rise to the same ERa protein which is expected due to the common acceptor splice site [13] and hence, at the protein level, the promoter selectivity is indistinguishable. However, from our new findings we infer that the limited predictive value of ERa-status may gain impetus from ESR1 mRNA assessments. We hypothesize that the molecular switch leading to promoter C activation by yet uncharacterized trans-acting factors does not lead to an increase of overall ER expression levels, but rather may destabilize protein turn over. A possible consequence could be that breast cancer cells may acquire a selective growth advantage through disruption of ER signaling and activation of alternative pathways for cell cycle stimulation.
In the future it will be important to better characterize this molecular switch to understand its influence on ER signaling in breast cancer. Yet, ESR1_C expression measurement may provide an immediate advantage for the assessment of breast cancer prognosis and prediction treatment outcome. This is particularly intriguing because RNA isolation from formalin-fixed paraffin-embedded tissues available from routine histopathologic practice together with easy to perform realtime PCR methodology provide the feasibility to supplement and refine current ERa diagnostic procedures. Our study for the first time introduces the ESR1_C isoform as a novel prognostic and endocrine treatment predictive marker for breast cancer management which should now be validated in larger clinical studies.
